Practical use of new oral anticoagulants in non-valvular atrial fibrillation
Abstract
Introduction. Atrial fibrillation is the most common arrhythmia in clinical practice. Its
incidence has been on the rise, reaching 8 % among those patients over the age of 80,
with a significant impact on morbimortality related to cerebrovascular complications.
The objective is to identify aspects of pharmacology and practical use of the new oral
anticoagulants in patients with non-valvular atrial fibrillation.
Division of topics covered. A non-systematic literature research was conducted in
databases and digital libraries (PubMed, Cochrane, Lilacs), including articles from
2008 to 2019, both in English and in Spanish that included the topics of interest.
A detailed description of the generalities of oral anticoagulants for atrial fibrillation
was made, including dabigatran, rivaroxaban, apixaban and edoxaban; monitoring
anticoagulant activity; description of the perioperative use of new oral anticoagulants
and reversal of anticoagulation for the new oral anticoagulants.
Conclusions. The use of new oral anticoagulants in patients with non-valvular atrial
fibrillation is a good alternative, with easy oral administration, without significant
increase in the risk of bleeding, compared to warfarin, and with the advantage of not
requiring continuous paraclinical monitoring.
References
Deshpande S, Catanzaro J , Wann S. Atrial fibrillation prevalence and scope of the problem. Cardiac Electrophysiology Clinics. 2014; 6 (1):1 - 4. doi: 10.1016/j. ccep.2013.10.006
Renoux C, Patenaude V , Suissa S. Incidence, mortality, and sex differences of non-valvular atrial fibrillation: A population-based study. Journal of the American Heart Association. 2014; 3 (6):1 - 8. doi: 10.1161/ JAHA.114.001402
Mulpuru S, Rabinstein A, Asirvatham S. Atrial fibrillation and stroke a neurologic perspective. Cardiac Electrophysiology Clinics 2014; 6(1):31 - 41. doi: 10.1016/j.ccep.2013.11.001
Castellano JM, Chinitz J, Willner J, Fuster V. Mechanisms of stroke in atrial fibrillation. Cardiac Electrophysiology Clinics. 2014; 6(1):5 - 15. doi: 10.1016/j. ccep.2013.10.007.
January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC, et al. 2014 AHA/ACC/HRS Guideline for the management of patients with atrial fibrillation: A report of the American College of cardiology/American heart association task force on practice guidelines and the heart rhythm society. Circulation. 2014; 130(23)201 -267. doi: 10.1161/ CIR.0000000000000041
Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal. 2016; 37(38):2893 - 2962. doi: 10.1093/eurheartj/ehw210
Harter K, Levine M, Henderson S. O. Anticoagulation drug therapy: a review. The Western Journal of Emergency Medicine. 2015; 16(1):11 - 7. doi: 10.5811/ westjem.2014.12.22933
Tatjana S, Gregory Y. Novel oral anticoagulants in non-valvular atrial fibrillation. Cardiovascular. Hematological Agents in Medicinal Chemistry. 2014 ; 26 (2) :115 - 129. doi: 10.1016/j.beha.2013.07.008
Cove C, Hylek E. An updated review of target-specific oral anticoagulants used in stroke prevention in atrial fibrillation, venous thromboembolic disease, and acute coronary syndromes. Journal of the American Heart Association. 2013; 2(5):115 - 219. doi: 10.1161/ JAHA.113.000136
Connolly S, Ezekowitz M, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. The New England Journal of Medicine. 2009; 361(12):1139 - 1151. doi: 10.1056/NEJMoa0905561
Hinojar R, Jiménez-Natcher J, Fernández-Golfín C, Zamorano J. New oral anticoagulants: a practical guide for physicians. European Heart Journal - Cardiovascular Pharmacotherapy. 2015; 1(2):134 - 145. doi: 10.1093/ehjcvp/pvv002
Ferns S, Naccarelli G. New Oral Anticoagulants. Their Role in Stroke Prevention in High-Risk Patients with Atrial Fibrillation. Medical Clinics of North America. 2015; 99(4):759 - 80. doi: 10.1016/j. mcna.2015.02.006
Shafeeq H , Tran T. New oral anticoagulants for atrial fibrillation: are they worth the risk? P&T : A Peer-Reviewed Journal for Formulary Management. [Internet]. 2014.[citado el 03 de Junio del 2019]; 39(1):54 - 64. Recuperado a partir de: https://www.ncbi.nlm. nih.gov/pmc/articles/PMC3956385/
Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. The New England Journal of Medicine. 2011; 365(10):883-91. doi: 10.1056/NEJMoa1009638
López-Sendón J, Merino J. Resultados e implicaciones del estudio ROCKET. Revista Española de Cardiología Suplementos. 2013; 13(C):42 - 46. doi: 10.1016/S1131-3587(13)70058-X
Mekaj Y, Mekaj A, Duci S, Miftari E. New oral anticoagulants: Their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events. Therapeutics and Clinical Risk Management. 2015(11):967 - 977. doi: 10.2147/TCRM.S84210
Shamoun F, Obeid H, Ramakrishna H. Novel anticoagulants in atrial fibrillation: Monitoring, reversal and perioperative management. BioMed Research International. 2015; 424031. doi: 10.1155/2015/424031
Steinberg B, Piccini, J. Anticoagulation in atrial fibrillation. British Medical Journal. 2014; 14(348) 2116. doi: 10.1136/bmj.g2116
Martínez-Rubio A, Martínez-Torrecilla R. Evidencias actuales de los nuevos anticoagulantes orales en el tratamiento de la fibrilación auricular no valvular: comparación de subestudios. Revista Espanola de Cardiologia. 2015; 68(3):185 - 189. doi: 10.1016/j. recesp.2014.07.017
Mateo J. Nuevos anticoagulantes orales y su papel en la práctica clínica. Revista Española de Cardiología Suplementos. 2013; 13(1 SUPPL.3) 33 - 41. doi: 10.1016/S1131-3587(13)70057-8
Hanley C, Kowey P. Are the novel anticoagulants better than warfarin for patients with atrial fibrillation?. Journal of Thoracic Disease. 2015; 7(2):165 - 171. doi: 10.3978/j.issn.2072-1439.2015.01.23
Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, et al. Updated European Heart Rhythm Association Practical Guide on the use of non-Vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2015; 15(5):625 - 651. doi: 10.1093/europace/euv309
Bounameaux H, Camm AJ. Edoxaban: An update on the new oral direct factor Xa inhibitor. Drugs. 2014; 74(11):1209-1231. doi: http://dx.doi.org/10.1007/ s40265-014-0261-1
Hapgood G, Butler J, Malan E, Chunilal S, Tran H. The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the hemoclot thrombin inhibitor assay in patient plasma samples. Thrombosis and Haemostasis. 2013 ; 110(2):308 - 315. doi: 10.1160/TH13-04-0301
Rechenmacher S, Fang, J. Bridging Anticoagulation Primum Non Nocere. Journal of the American College of Cardiology. 2015; 66(12):1392-13403. doi: 10.1016/j.jacc.2015.08.002
Díaz J, Duque M, Duque L, Uribe W, Medina E, Marín J. Tratamiento perioperatorio del paciente con antiagregación o anticoagulación. Revista Colombiana de Cardiología. 2012; 19(5): 252 - 259. doi: 10.1016/ S0120-5633(12)70141-9
Lai A, Davidson N, Galloway S, Thachil J. Perioperative management of patients on new oral anticoagulants. The British journal of surgery. 2014; 101(7): 742 - 9. doi: 10.1002/bjs.9485
Skaistis J, Tagami T. Risk of fatal bleeding in episodes of major bleeding with new oral anticoagulants and Vitamin K antagonists: A systematic review and me ta-Analysis. PLoS ONE. 2015; 10(9): e0137444. doi: 10.1371/journal.pone.0137444
Ansell J. Reversal Agents for the Direct Oral Anticoagulants. Hematology/Oncology Clinics of North America. 2016; 30(5): 1085-1098. doi: 10.1016/j. hoc.2016.05.006
Siegal DM, Curnutte JT, Connolly SJ, Lu G, Conley PB, Wiens BL, et al. Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity. N Engl J Med. 2015; 373(25):2413-2424. doi: 10.1056/NEJMoa1510991
Pollack CV, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, et al. Idarucizumab for Dabigatran Reversal. NEnglJMed. 2015; 373(6):511 - 520. doi: 10.1056/NEJMoa1502000
Ansell JE, Bakhru SH, Laulicht BE, Steiner SS, Grosso M, Brown K, et al. Use of PER977 to Reverse the Anticoagulant Effect of Edoxaban. New England Journal of Medicine. 2014; 371(22):2141 - 2142. doi: 10.1056/NEJMc1411800
Connolly SJ, Crowther M, Eikelboom JW, Gibson CM, Curnutte JT, Lawrence JH, et al. Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors. N Engl J Med. 2019; 380(14):1326 - 1335. doi: 10.1056/NEJMoa1814051.
Downloads
| Article metrics | |
|---|---|
| Abstract views | |
| Galley vies | |
| PDF Views | |
| HTML views | |
| Other views | |
